Fatty Liver, Nonalcoholic, Liver Fibrosis, Type2 Diabetes
Conditions
Keywords
Type 2 Diabetes, Metabolic associated fatty liver disease,, Prolactin
Brief summary
Metabolic associated fatty liver disease (MAFLD) has currently reached a worldwide epidemic. Serum PRL levels within or outside physiological range have been found to affect metabolic homeostasis differently. However, the relationship between serum PRL and MAFLD among diabetic patients is unclear. The investigators aimed to explore the association between serum PRL and the risk of MAFLD in patients with type 2 diabetes (T2DM).
Interventions
OTHERnon-invasive method, Fibroscan
Liver Ultrasound and transient elastography (FibroScan®)
Sponsors
Shen Qu
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* aged 18\ 65 years old, * underwent the laboratory tests, hepatic ultrasonography, and valid transient elastography (FibroScan) examination
Exclusion criteria
* other known chronic liver diseases, such as chronic hepatitis B or C, autoimmune hepatitis, and haemochromatosis * pre-existing active cancer, renal dysfunction, severe liver dysfunction, congestive heart failure or free abdominal fluid * history of hyperthyroidism or hypothyroidism, pituitary diseases, and other types of diabetes * significant alcohol consumption * pregnancy * receiving any therapeutic methods that could lead to liver steatosis or fibrosis, influence the glucolipid metabolism, or PRL levels, such as lipid-lowering, and PRL-lowering agents (bromocriptine) within 6 months prior to this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Diagnosis of MAFLD proposed by the international expert consensus statement in 2020 | 2019-2024 | MAFLD was diagnosed based on evidence of ultrasonically diagnosed hepatic steatosis in addition to one of the three criteria proposed by the international expert consensus statement in 2020, namely overweight/obesity, T2DM, or metabolic dysregulation regardless of alcohol consumption or other concomitant liver diseases. Metabolic dysregulation was defined by the presence of at least two metabolic risk abnormalities found in lean or normal weight patients, including hypertension, dyslipidemia, hyperglycemia, IR, and high CRP levels. |
| PRL | 2019-2024 | serum prolactin levels |
| High PRL (HP) | 2019-2024 | HP was defined as serum PRL ≥ 324mIU/L in males or ≥ 496mIU/L in females according to the normal reference value of serum PRL in our hospital. |
| Normal PRL (NP) | 2019-2024 | NP was defined as serum PRL \< 324mIU/L in males or \< 496mIU/L in females. |
| Diagnosis of hepatic steatosis | 2019-2024 | Those who have hepatic steatosis if CAP value ≥ 248 dB/m, which was obtained from transient elastography (FibroScan®) using the M probe or the XL probe. |
| Diagnosis of significant hepatic fibrosis | 2019-2024 | those who have significant hepatic fibrosis if LSM ≥ 7.0 kPa and ≥ 6.2 kPa (using either M or XL probes) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| High CRP | 2019-2024 | plasma CRP \> 2 mg/L |
| Homeostasis model assessment of IR (HOMA-IR) | 2019-2024 | HOMA-IR was calculated as described by Matthews et al: FPG (mmol/L) × FINS (mU/L) /22.5. |
| High HOMA-IR | 2019-2024 | HOMA-IR≥ 2.5 |
| Hypertension | 2019-2024 | it was defined by blood pressure ≥130/85mmHg or antihypertensive drugs. |
| Dyslipidemia | 2019-2024 | it was defined by plasma TG ≥ 1.7mmol/L in the total population or plasma HDL-C \< 1.0 mmol/L for men and \< 1.3 mmol/L for women, or specific drug treatment. |
| Overweight or obesity | 2019-2024 | it was defined as BMI ≥ 23 kg/m2 in Asians. |
| Abdominal obesity | 2019-2024 | It was diagnosed when WC ≥ 90/80 cm in Asian men and women. |
| T2DM | 2019-2024 | it was diagnosed according to the guideline for the prevention and treatment of T2DM in China (2020 edition) |
Countries
China
Contacts
Primary ContactShen Qu
Outcome results
None listed